A Phase Ib/II Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in HR+ breast Patients with Locally Advanced or Metastatic post first line with a CDK6/6 inhibitor. Oral Pan AKT inhibitor. Open to patients regardless of PIK3CA mutation status.
Eligible patients for this study must have either (1) progressive disease whilst receiving an endocrine therapy (AI or a SERM), and/or a CDK4/6 inhibitor for locally advanced or metastatic disease; or (2) relapsed with metastatic disease whilst receiving an ET (AI or SERM), and/or a CDK4/6 inhibitor, and/or chemotherapy in adjuvant setting. No more than 2 prior lines of systemic treatments for locally advanced or metastatic disease are allowed for this study, including 1-2 prior lines of endocrine therapy, with/without CDK4/6 inhibitor (up to 1 therapy), and/or chemotherapy (up to 1 therapy).
Learn More at clinicaltrials.gov
To participate in this trial please call: 310-582-7448